Influence of *interleukin-18* polymorphisms on kidney transplantation outcomes: A meta-analysis

Thanee Eiamsitrakoon^{1,2}, PhuntilaTharabenjasin^{1*}, Noel Pabalan¹, Rungrawee Mongkolrob¹, Aporn Bualuang¹ and Adis Tasanarong^{1,2}

¹ Chulabhorn International College of Medicine, Thammasat University.

Cooperative Learning Center, Piyachart 2 Building, 99 Moo 18, Paholyothin Rd., Klong Neung, Klong Luang, Rangsit, Pathumthani 12120 Thailand

² Nephrology Unit, Faculty of Medicine, Thammasat University. 99/209 Moo 18, Paholyothin Rd., Klong Neung, Klong Luang, Rangsit, Pathumthani 12120 Thailand

Thanee Eiamsitrakoon

Email: thaneeeiams@gmail.com

Noel Pabalan

1

2 3 4

5

13 14

15

16 17

18

19 20

21

22 23

24

25 26

27

28 29 30

31 32

40

41 42

43

46

60

Email: noelpabalan@ymail.com

Rungrawee Mongkolrob Email: scrmr303@gmail.com

Aporn Bualuang

Email: tent79@hotmail.com

Adis Tasanarong

Email: adis_tasanarong@hotmail.com

Corresponding author:

Phuntila Tharabenjasin¹*

Address correspondence to Phuntila Tharabenjasin,

Chulabhorn International College of Medicine, Thammasat University,

Cooperative Learning Center, Piyachart 2 Bulding, 99 Moo 18 Klong Luang, Rangsit, Pathumthani 12120,

Thailand

Email: pacezen@yahoo.com

Telephone: (66) 2564-4440-9 Ext 7589; (66) 91-959-8915

P orcid.org/0000-0002-4191-2802

Abstract

Aim: Allograft survival post-kidney transplantation (KT) are in large part attributed to genetics, which render the recipient susceptible or protected from allograft rejection. KT studies involving single nucleotide polymorphisms (SNPs) have reported the association of interleukin-18 (IL-18) with KT and its role in allograft rejection. However, the reported outcomes been inconsistent, prompting a meta-analysis to obtain more precise estimates. Methods: We posed two hypotheses about the IL-18 SNPs: their association with KT (H1), and increase or decrease in the risks of allograft rejection (H2). Using standard genetic models, we estimated odds ratios [ORs] and 95% confidence intervals by comparing the IL-18 genotypes between two groups: (i) patients and controls for H1 (GD: genotype distribution analysis); (ii) rejectors and non-rejectors for H2 (allograft analysis). Multiple comparisons were corrected with the Holm-Bonferroni (HB) test. Subgrouping was ethnicity-based (Asians and Caucasians). Heterogeneity was outlier-treated and robustness of outcomes was sensitivity-treated. Results: This metaanalysis generated eight significant outcomes, which HB filtered into four core outcomes, found in the dominant/codominant models. Two of the four were in GD, indicating associations of the IL-18 SNPs with KT (ORs 1.34 to 1.39, 95% CIs 1.13-1.70, $P_{\rm HB}$ = .0007-.004). The other two were in allograft analysis indicating reduced risk with HB P-values of .03 for overall (OR 0.74, 95% CI 0.56-0.93) and Asian (OR 0.70, 95% CI 0.53-0.92). In contrast to the protected Asian subgroup, Caucasians showed non-significant increased risk (OR 1.20. 95% CI .82-1.75, Pa = .35). Sensitivity treatment conferred robustness to all the core outcomes. **Conclusions:** Overall association of IL-18 SNPs with KT was significant (up to 1.4-fold) and Asians KT recipients were protected (up to 30%). Enabled by outlier treatment, these findings were supported by non-heterogeneity and robustness. More studies may confirm or modify our findings.

| 62 | Abbreviations | |
|------------|-----------------------|--|
| 63 | * | robust (all other significant outcomes were non-robust) |
| 64 | \checkmark | significant outcome that survived the Bonferroni correction |
| 65 | A | adenine |
| 66 | AM | analysis model |
| 67 | C | cytosine |
| 68 | Co | codominant genetic model |
| 69 | CB | Clark-Baudouin |
| 70 | CC | homozygous genotype |
| 71 | CI | confidence interval |
| 72 | Do | dominant genetic model |
| 73 | de | decreased risk |
| 74 | du | duplicate |
| 75 | EH | eliminated heterogeneity |
| 76 | Fe | fixed-effects |
| 77 | G | guanine |
| 78 | GD | genotype distribution |
| 79 | GS | gained significance |
| 80 | H1 | hypothesis 1 (GD analysis) |
| 81 | H2 | hypothesis 2 (allograft analysis) |
| 82 | het | heterogeneity |
| 83 | Но | homozygous genetic model |
| 84 | hc | higher in controls |
| 85 86 | hp | higher in patients |
| 87 | HWE | Hardy-Weinberg Equilibrium |
| 88 | <i>IL-18</i> IL-18 | interleukin-18 gene interleukin-18 protein |
| 89 | in | increased risk |
| 90 | KT | kidney transplantation |
| 91 | LD | linkage disequilibrium |
| 92 | Log OR | logarithm of standardized odds ratio |
| 93 | maf | minor allele frequency |
| 94 | n | number of studies |
| 95 | NRJ | non-rejector |
| 96 | OR | odds ratio |
| 97 | P^{a} | P-value for association |
| 98 | P^{b} | P-value for heterogeneity |
| 99 | PRO | pre-outlier |
| 100 | PSO | post outlier |
| 101 | I^2 | measure of variability |
| 102 | Rc | recessive genetic model |
| 103 | [R] | Reference |
| 104 | Re | random-effects |
| 105 | RH | reduced heterogeneity |
| 106 | RJ | rejector |
| 107 | RNS | retained non-significance |
| 108 | SD | standard deviation |
| 109 | SE | standard error |
| 110 | sig | significant |
| 111 | SNP | single nucleotide polymorphism |
| 112 113 | var | variant |
| 113 | Wt war | wild-type homozygotes |
| | wt-var | heterozygote |
| 115 | | |
| 116 | | |
| 117 | Keywords: IL-18 polyi | morphisms, allograft, kidney transplantation, renal, meta-analysis |
| 118 | | |
| 119 | | |
| 120 | | |
| | | |

1. Introduction

121

122 123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145146147148

The end-stage of renal failure resulting from kidney disease points to kidney transplantation (KT) as the optimal therapeutic choice [1,2]. The transplanted material (allograft) in the recipient is successful only if it is not rejected [3]. Unrejected allografts are expected to perform the functions as normal kidneys. Normal post-KT graft outcomes depend on immunology where variation in immune responses of the recipient is genetically influenced [4]. This variation may help individualize immunosuppressive regimens by identifying alleles that could increase risk or confer protection for immune-mediated complications [5]. Cytokines are potent immunomodulatory molecules that mediate the immune response [6]. Their production has been shown to be genetically controlled and polymorphisms of many cytokine genes affect their transcriptional activities, resulting in individual variations in cytokine production [7]. Of the cytokine-related factors, interleukin-18 (*IL-18*) has been identified as a post-KT biomarker [8]. Single nucleotide polymorphisms (SNPs) have been reported to be associated with post-KT outcomes [9]. Studies of IL-18 SNP associations with KT outcomes have promoted better understanding of renal disease immunology, providing greater insight into the biology of KT. However, the primary study conclusions have varied in their degree of concurrence. A meta-analysis addressing this variation may yield clearer estimates of the role of *IL-18* SNPs in KT outcomes. In this meta-analysis, we operated on two hypotheses about the IL-18 SNPs, their association with KT (H1), and increase or decrease in the risks of AR (H2). In H1, we examine genotype distribution (GD) between patients and healthy controls. In H2 allograft analysis, we compare rejector (RJ) with nonrejector (NRJ) patients. Outcomes from this this might provide useful clinical information for the genetics of KT.

150151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

2. Methods **Selection of studies** We searched MEDLINE using PubMed, Google Scholar and Science Direct for association studies as of September 24, 2019. The terms used were "interleukin", "IL-18", "cytokine", "polymorphism", "allograft" and "renal transplantation" as medical subject heading and text. References cited in the retrieved articles were also screened manually to identify additional eligible studies. In cases of duplicate articles, we selected the one with a later date of publication. Inclusion criteria were (1) case—control design evaluating the association between IL-18 polymorphisms and KT outcomes. (2) IL-18 genotype frequencies that compare KT patients and healthy controls, NR and NRJ. (3) Sufficient genotype frequency data to enable calculation of the odds ratios (ORs) and 95% confidence intervals (CIs). Exclusion criteria were (1) not involving renal allografts or post-KT outcomes; (2) reviews; (3) not about the *IL-18* polymorphisms and (4) studies whose genotype or allele frequencies were unusable or absent. SNP groupings The included articles examined two IL-18 SNPs, rs187238 and rs1946518, each presented with genotype data (Tables S2 and S3). Observed phenotypic associations have been attributed to the proximity of two SNPs [10,11]. NCI LDLINK (https://ldlink.nci.nih.gov/) results shows that the two SNPS are in linkage disequilibrium (LD). LD is the correlation between alleles located near each other [12] which is measured in terms of D' with a value of 1 indicating complete LD [13]. Therefore, *IL-18* SNPs (rs187238 and rs1946518) with D' values of 1.00 in this study (Table S1) were combined in the analysis (Tables S2 and S3). The rationale for combining rests on the assumption that SNPs in LD yield similar associations in the phenotype.

176177

178

179

180

181

182

183

184

185

186

187

188

189 190

191

192

193

194

195

196

197

198

199

200

201

Data extraction, HWE and methodological quality Two investigators (TE and NP) independently extracted data and arrived at a consensus. The following information was obtained from each publication: first author's name, year of the study, country of origin, ethnicity, age of the subjects in years, *IL-18* SNPs (rs number) (Table 1). Sample sizes as well as genotype data between the RJ and NRJ were also extracted along with calculated outcome of the minor allele frequency (maf) (Tables S2 and S3). The Hardy-Weinberg Equilibrium (HWE) was assessed using the application in https://ihg.gsf.de/cgi-bin/hw/hwa1.pl. The Clark-Baudouin (CB) scale was used to evaluate methodological quality of the included studies [14]. CB criteria include P-values, statistical power, correction for multiplicity, comparative sample sizes between cases and controls, genotyping methods and the HWE. In this scale, low, moderate and high have scores of < 5, 5-6 and \geq 7, respectively. **Meta-analysis** We estimated ORs and 95 % CIs using two overall approaches: (i) genotype distribution (GD) between cases and healthy controls and (ii) allograft wherein RJ were compared with NRJ. Thus, both were KT outcomes were analysed separately. Calculated pooled ORs for GD were either higher in patients (hp) or higher in controls (hc); in allograft, they were either increased (in) or decreased (de), indicating risk for rejection. Standard genetic modeling was used, wherein we compared the following, (i) recessive (Rc: wt-wt versus wt-var + var-var), (ii) dominant (Do: wt-wt + wt-var versus var-var) and (iii) codominant (Co: wt versus var) effects. Heterogeneity between studies was estimated with the χ^2 -based O test [15], with threshold of significance set at $P^{b} < .10$. Heterogeneity was also quantified with the I^{2} statistic which measures variability between studies [16]. Evidence of functional similarities in population features of the studies warranted using the fixed-effects model [17], otherwise the random-effects model [18] was used. Sources of heterogeneity were detected with the

203

204

205

206

207

208

209

210

211212

213214

215

216

217

218

219

220

221

222

223

224225

226

227

228

229

Galbraith plot [19] followed by re-analysis (outlier treatment). Of note, outlier treatment dichotomized the comparisons into pre-outlier (PRO) and post-outlier (PSO). Sensitivity analysis, which involves omitting one study at a time and recalculating the pooled OR, was used to test for robustness of the summary effects. The low number of studies precluded assessment of publication bias. Multiple associative outcomes were Holm-Bonferroni (HB) corrected. Data were analysed using Review Manager 5.3 (Cochrane Collaboration, Oxford, England), SIGMAPLOT 11.0 and SIGMASTAT 2.03 (Systat Software, San Jose, CA, USA). 3. Results Search outcomes and study features Figure 1 outlines the study selection process in a PRISMA-sanctioned flowchart (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Initial search resulted in 39 citations, followed by a series of omissions that eventually yielded four articles for inclusion [20-23]. Table 1 shows two Asian [20,21] and two Caucasian [23,22] articles with middleage profile of the KT subjects (mean \pm SD: 37.8 years \pm 5.9). Three [23,22,21] of the four included articles examined the two *IL-18* polymorphisms (rs187238 and rs1946518). Methodological quality of the component studies was moderate with a mean \pm SD of 6.37 \pm 1.24. Tables S2 and S3 show seven studies each for GD and allograft analyses. This metaanalysis followed the PRISMA guidelines (Table S5). Meta-analysis outcomes Table 2 delineates the overall pooled ORs by direction of effect, where GDs were higher in patients (hp) (OR > 1.00) but decreased risk (de) in the allograft analysis (OR < 1.00). The results generated 27 comparisons (Tables 2-3), eight of which were statistically significant $(P^{a} < .05)$. Of the eight, four withstood the HB correction, which were considered the core findings. Of the four, two were in GD showing hp effects in the Do/Co models (OR 1.34-

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246 247 248

249

250

251

252

253

254

255

1.39, 95% CIs 1.13 to 1.70, $P_{\rm HB} = .0007 - .004$). The other two core outcomes (at HB *P*-values of .03) were in allograft analysis indicating reduced risk in the Co model, one in the overall (OR 0.73, 95% CI 0.56-0.93) and the other in Asians (OR 0.70, 95% CI 0.53-0.92). This Asian contrasted with the increased risk outcome in Caucasians (OR 1.20, 95% CI 0.82-1.75, $P^a = 0.35$) Of note, all four core outcomes were outlier-derived (PSO). The mechanism of outlier treatment for IL-18 in the Co model of allograft analysis is visualized in Figures 2-4. Figure 2 shows the PRO forest plot with a non-significant ($P^a = .48$) and heterogeneous ($P^b = .02$, $I^2 = .08$) 60%) pooled effect indicating reduced risk (OR 0.89 95% CI 0.63 to 1.25). The Galbraith plot identified the two studies [22,21] as the sources of heterogeneity (outliers), located above the +2 confidence limit (Figure 3). In Figure 4, the PSO outcome (outliers omitted) shows reduced heterogeneity ($P^b = .16$, $I^2 = 39\%$); reduced risk effect (OR 0.73 95% CI 0.56 to 0.93) and gained significance ($P^a = .01$). This operation is numerically summarized in Table 2. Sensitivity treatment deemed the core outcomes to be robust. 4. Discussion The main findings of this study showed that *IL-18* SNPs were associated with KT outcomes, more specifically, the allograft analysis indicated reduced risks of rejection. Subgroup analysis identified Asian KT recipients with the *IL-18* SNPs as protected from allograft rejection which contrasted with the increased risk for the Caucasian subgroup. The core status of having withstood HB and robustness of our principal findings underpin the strength of evidence in this study. Furthermore, outlier treatment unraveled significant and nonheterogeneous associations that were not present in the component single-study outcomes. Conflicting outcomes between primary studies may be attributed to their lack of power and

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279280

281

small sample sizes. Underpowered outcomes appear to be common in candidate gene studies [24] and are prone to the risk of Type 1 error. In spite of the evidence for associations, the complexity of allograft rejection involves interactions between genetic and non-genetic factors allowing for the possibility of environmental involvement. Gene-gene and geneenvironment interactions have been reported to have roles in associations of other polymorphisms with post-KT allograft rejection. One article [21] examined another gene polymorphism (vascular endothelial growth factor (VEGF). All articles acknowledged geneenvironment interaction. Addressing gene-gene and gene-environment interactions may help address the pathophysiological significance of IL-18 in allograft failure post-KT. All the included articles mentioned haplotype analysis with one presenting haplotype data [21]. Focus on *IL-18* haplotypes have been suggested for future association studies [9]. The crucial role of *IL-18* in kidney physiology lies in its involvement in the filtration, integrity and permeability of the glomerular basement membrane [25]. IL-18 expression in the renal epithelium might be important in triggering specific immune response manifested as acute graft rejection [26]. Increased IL-18 production promotes enhanced endothelial permeability and augmented leukocyte migration into the allograft, promoting a clinically recognized rejection episode [21]. A study demonstrated upregulation of IL-18 production in patients with acute rejection of kidney allograft [26]. Moreover, another study found significantly higher levels of IL-18 in culture biopsies from patients with acute rejection in comparison to stable KT patients [27]. Urinary IL-18 has been found to be an early, noninvasive and accurate predictor for dialysis within the first week of KT [28]. 5. Strengths and limitations Two strengths of our study were: (i) outlier treatment was key to generating significance and reducing heterogeneity; and (ii) subgrouping identified Asians as significantly protected and

Caucasians as non-significantly susceptible to allograft rejection. Limitations include: (i) the component studies were underpowered, however, sample sizes were adequate at the aggregate level with 624 cases/634 controls in GD (Table S2) and 147 cases/674 controls in allograft (Table S3). (ii) Genotype distributions of the control population in some studies deviated from the HWE (Tables S2 and S3) and it might be a source of potential bias in our study.

6. Conclusions

- To our knowledge, this is the first meta-analysis with evidence that may render *IL-18* useful as a prognostic marker in allograft rejection post-KT. Additional well-designed studies exploring other parameters may confirm or modify our results in this study.
- 293 Conflict of interest
 - The authors have no conflicts of interest to declare

296 Funding

297 None

282

283

284

285

286

287

288

292

294

295

298299

300

305306307

308 309 310

311

312

Supporting information

| 301 | Table S1 | LD matrix | DOCX |
|-----|----------|---------------------------------|------|
| 302 | Table S2 | Quantitative features GD | DOCX |
| 303 | Table S3 | Quantitative features Allograft | DOCX |
| 304 | Table S4 | PRISMA checklist | DOCX |

References

- 1. Howard K, Salkeld G, White S, McDonald S, Chadban S, Craig JC, Cass A (2009) The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology 14 (1):123-132. doi:10.1111/j.1440-1797.2008.01073.x
- 2. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G (2007) Chronic kidney disease as a global public health problem: approaches and initiatives a position statement from Kidney Disease
- 316 Improving Global Outcomes. Kidney international 72 (3):247-259. doi:10.1038/sj.ki.5002343
- 3. Critchley WR, Fildes JE (2012) Graft rejection endogenous or allogeneic? Immunology 136
- 318 (2):123-132. doi:10.1111/j.1365-2567.2012.03560.x
- 4. Pawlus J, Sierocka A, Tejchman K, Zietek Z, Romanowski M, Pawlik A, Sienko J, Zukowski M,
- 320 Ciechanowski K, Ostrowski M, Sulikowski T (2014) The impact of interleukin 12B (1188A>C),
- 321 interleukin 16 (-295T>C), and interleukin 18 (607C>A, 137G>C) gene polymorphisms on long-term
- renal transplant function and recipient outcomes. Transplantation proceedings 46 (6):2079-2082.
- 323 doi:10.1016/j.transproceed.2014.06.019

- 5. Kruger B, Schroppel B, Murphy BT (2008) Genetic polymorphisms and the fate of the transplanted
- 325 organ. Transplantation reviews 22 (2):131-140. doi:10.1016/j.trre.2007.12.002
- 326 6. Seeger H, Lindenmeyer MT, Cohen CD, Jaeckel C, Nelson PJ, Chen J, Edenhofer I, Kozakowski
- 327 N, Regele H, Boehmig G, Brandt S, Wuethrich RP, Heikenwalder M, Fehr T, Segerer S (2018)
- 328 Lymphotoxin expression in human and murine renal allografts. PloS one 13 (1):e0189396.
- 329 doi:10.1371/journal.pone.0189396
- 7. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in
- 331 the human tumor necrosis factor alpha promoter on transcriptional activation. Proceedings of the
- National Academy of Sciences of the United States of America 94 (7):3195-3199.
- 333 doi:10.1073/pnas.94.7.3195
- 8. Herath S, Erlich J, Au AYM, Endre ZH (2019) Advances in Detection of Kidney Transplant Injury.
- 335 Molecular diagnosis & therapy 23 (3):333-351. doi:10.1007/s40291-019-00396-z
- 9. Phelan PJ, Conlon PJ, Sparks MA (2014) Genetic determinants of renal transplant outcome: where
- 337 do we stand? Journal of nephrology 27 (3):247-256. doi:10.1007/s40620-014-0053-4
- 338 10. Liu Y, Lin N, Huang L, Xu Q, Pang G (2007) Genetic polymorphisms of the interleukin-18 gene
- and risk of prostate cancer. DNA and cell biology 26 (8):613-618. doi:10.1089/dna.2007.0600
- 11. Wei YS, Lan Y, Liu YG, Tang H, Tang RG, Wang JC (2007) Interleukin-18 gene promoter
- polymorphisms and the risk of esophageal squamous cell carcinoma. Acta oncologica 46 (8):1090-
- 342 1096. doi:10.1080/02841860701373595
- 12. Borecki I (2001) Linkage and Association Studies. In: Encyclopedia of Life Sciences. John Wiley
 Sons, Ltd.
- 345 13. Lewontin RC (1988) On measures of gametic disequilibrium. Genetics 120 (3):849-852
- 14. Clark MF, Baudouin SV (2006) A systematic review of the quality of genetic association studies in
- 347 human sepsis. Intensive Care Med 32 (11):1706-1712
- 348 15. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-
- 349 analyses. Bmj 327 (7414):557-560
- 350 16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21
- 351 (11):1539-1558
- 352 17. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (4):719-748
- 354 18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7 (3):177-188
- 355 19. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7 (8):889-894
- 357 20. Kim CD, Ryu HM, Choi JY, Choi HJ, Choi HJ, Cho JH, Park SH, Won DI, Kim YL (2008)
- 358 Association of G-137C IL-18 promoter polymorphism with acute allograft rejection in renal transplant
- 359 recipients. Transplantation 86 (11):1610-1614. doi:10.1097/TP.0b013e31818870c4
- 360 21. Mittal RD, Srivastava P, Singh V, Jaiswal P, Kapoor R (2011) Association of common variants of
- vascular endothelial growth factor and interleukin-18 genes with allograft survival in renal transplant
- 362 recipients of North India. DNA and cell biology 30 (5):309-315. doi:10.1089/dna.2010.1138
- 363 22. Kolesar L, Novota P, Krasna E, Slavcev A, Viklicky O, Honsova E, Striz I (2007) Polymorphism of
- interleukin-18 promoter influences the onset of kidney graft function after transplantation. Tissue
- 365 antigens 70 (5):363-368. doi:10.1111/j.1399-0039.2007.00913.x
- 23. do Nascimento WG, Ciliao DA, Genre J, Gondim DD, Alves RG, Hassan ND, Lima FP, Pereira
- 367 MG, Donadi EA, de Oliveira Crispim JC (2014) Genetic polymorphisms of Interleukin-18 are not
- associated with allograft function in kidney transplant recipients. Genetics and molecular biology 37 (2):343-349
- 370 24. Dumas-Mallet E, Button KS, Boraud T, Gonon F, Munafo MR (2017) Low statistical power in
- 371 biomedical science: a review of three human research domains. Royal Society open science 4
- 372 (2):160254. doi:10.1098/rsos.160254
- 373 25. Chen Y, Dawes PT, Packham JC, Mattey DL (2011) Interaction between smoking and
- 374 polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease
- and myocardial infarction in rheumatoid arthritis. The Journal of rheumatology 38 (5):802-809.
- 376 doi:10.3899/jrheum.101095
- 377 26. Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, Jaresova M, Lodererova A, Bohmova R,
- 378 Valhova S, Slavcev A, Vitko S (2005) Interleukin 18 (IL-18) upregulation in acute rejection of kidney
- 379 allograft. Immunology letters 99 (1):30-35. doi:10.1016/j.imlet.2005.01.010
- 380 27. de Oliveira JG, Xavier PD, Sampaio SM, Tavares IS, Mendes AA (2002) The synthesis by fine-
- needle aspiration biopsy cultures of IL-7, IL-16 and IL-18 is significantly associated with acute
- 382 rejection in kidney transplants. Nephron 92 (3):622-628. doi:10.1159/000064106

28. Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR (2010) IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. Journal of the American Society of Nephrology: JASN 21 (1):189-197. doi:10.1681/ASN.2009030264

TABLE 1 Characteristics of the included studies in *interleukin-18* associations with kidney transplantation outcomes

| First author | [R] | Year | Country | Ethnicity | Age (years) mean ± SD RJ / NRJ | IL-18 SNPs | СВ |
|---------------|-----|------|--------------|-----------|-----------------------------------|---------------------|----|
| Kim | 20 | 2008 | Korea | Asian | 33.9 ± 9.4 / 36.1 ± 11.1 | rs187238 | 10 |
| Mittal | 21 | 2011 | India | Asian | $33.2 \pm 12.6 / 38.2 \pm 11.1$ | rs187238, rs1946518 | 6 |
| Kolesar | 22 | 2007 | Czechlovakia | Caucasian | 49.6 (patients) | rs187238, rs1946518 | 7 |
| do Nascimento | 23 | 2014 | Brazil | Caucasian | $33.1 \pm 12.4 / 40.5 \pm 13.0$ | rs187238, rs1946518 | 7 |

[R] Reference; IL-18,; SD, standard deviation; RJ, rejector; NRJ, non-rejector; SNP, single nucleotide polymorphism; CB, Clark-Baudouin

TABLE 2 Summary outcomes for associations of interleukin-18 polymorphisms with kidney transplantation outcomes

| | | Те | est of associati | ion | | | Test c | | | | | | Test o | • | | | | |
|-----------|---|------|------------------|------------------|--------|------------|-----------------------|----|---|------|-----------|------------|--------|------------|-----------------------|----|-----|-------------------------|
| | n | OR | 95% CI | P^{a} | | $P^{ m b}$ | I ² (%) | AM | n | OR | 95% CI | $P^{ m a}$ | | $P^{ m b}$ | I ² (%) | AM | out | ect of clier ment |
| | | | | PRC |) | | | | | | | PSO | | | | | Sig | Het |
| GD | | | | | Status | | | , | | | | | Status | | | | | - |
| Rc | 7 | 1.33 | 0.99-1.79 | .06 | hp | .12 | 41 | Fe | | | | | | | | | | |
| Do | 7 | 1.24 | 0.93-1.65 | .14 | hp | .03 | 57 | Re | 6 | 1.39 | 1.13-1.70 | .002 * | hp | .23 | 28 | Fe | GS | RH |
| Co | 7 | 1.17 | 0.96-1.44 | .12 | hp | .04 | 54 | Re | 5 | 1.34 | 1.13-1.58 | .0007* | hp | .22 | 31 | Fe | GS | RH |
| Allograft | | | | | Risk | | | | | | | | Risk | | | | | |
| Rc | 7 | 0.84 | 0.55-1.29 | .43 | de | .14 | 38 | Fe | | | | | | | | | | |
| Do | 7 | 0.74 | 0.55-0.98 | .04 | de | .46 | 0 | Fe | | | | | | | | | | |
| Co | 7 | 0.89 | 0.63-1.25 | .48 | de | .02 | 60 | Re | 5 | 0.73 | 0.56-0.93 | .01 * | de | .16 | 39 | Fe | GS | RH |

GD, genotype distribution; Rc, recessive; Do, dominant; Co, co dominant; n, number of studies; OR, odds ratio; CI, confidence interval; P^a , P-value for association; in, increased risk; de, decreased risk; hp, higher in patients; P^b , P-value for heterogeneity (Het); I^a , measure of variability; AM, analysis model; Re, random-effects; Fe, fixed-effects; PRO, pre-outlier; PSO, post-outlier; GS, gained Sig; RH, reduced Het; values in bold indicate Sig associations; \star core outcome.

TABLE 3 Subgroup outcomes for associations of interleukin-18 polymorphisms with kidney transplantation outcomes

| | | Те | st of associat | | Test of heterogeneity | | | Test of association | | | | | | Test o | - | | | |
|--------------------|---|----------------------|------------------------|--------------------|--------------------------|----------------|-----------------------|---------------------|---|------|--------------|------------------|--------------|------------------|-----------------------|----|-----|-----------------------|
| | n | OR | 95% CI | P^{a} | | $P^{ m b}$ | I ² (%) | AM | n | OR | 95% CI | P^{a} | | P^{b} | I ² (%) | AM | out | ct of lier ment |
| | | | | PRO |) | | | | | | | PSO | | | | | Sig | Het |
| GD Asian | | | | | Charters | | | | | | | | Ctatus | | | | | |
| Asian Rc | 0 | 1 47 | 0.71.0.04 | 20 | Status hp | 0.09 | 58 | Re | 2 | 1.05 | 0.76-2.04 | .38 | Status hp | .16 | 40 | Fe | RNS | RH |
| Do | 3 | $\frac{1.47}{1.12}$ | 0.71-3.04 0.71-1.77 | .29 .62 | пр hp | _ | 50 71 | Re | 2 | 1.25 | 0.67-1.22 | .30 .51 | hc | .16 | 49 50 | Fe | RNS | RH |
| Co | 3 | | 0.86-1.60 | | пр hp | 0.03 | 63 | Re | | 0.90 | 0.0/-1.22 | _ | hc | .69 | 50 0 | Fe | RNS | EH |
| Caucasian | 3 | 1.17 | 0.80-1.00 | .32 | np | 0.07 | 03 | Ke | 2 | 0.99 | 0./6-1.20 | .94 | ne | .09 | U | ге | KNO | EII |
| Rc | 4 | 1.00 | 0.70-1.67 | .71 | hp | 0.05 | 26 | Fe | | | | | | | | | | |
| Do | 4 | 1.09 | 1. 04-1.80 | ./1 . 03 | пр hp | $0.25 \\ 0.11$ | 50 50 | Fe | | | | | | | | | | |
| Co | 4 | 1.3 7 1.17 | 0.86-1.61 | .0 3 .32 | пр hp | 0.11 | 60 | Re | | | 1.04-1.66 | .02 | hp | .16 | 40 | Fe | GS | RH |
| | 4 | 1.1/ | 0.60-1.01 | .32 | np | 0.00 | 00 | Ke | 3 | 1.32 | 1.04-1.00 | .02 | np | .10 | 40 | ге | GO | КΠ |
| Allograft Asian | | | | | Risk | | | | | | | | Risk | | | | | |
| Rc | 5 | 0.87 | 0.38-2.00 | .75 | de | 0.05 | 58 | Re | 4 | 0.62 | 0.35-1.10 | .10 | de | .12 | 49 | Fe | RNS | RH |
| Do | 5 | 0.70 | 0.50-0.98 | .04 | de | 0.25 | 25 | Fe | | | | | | | | | | |
| Co | 5 | 0.78 | 0.52-1.16 | .22 | de | 0.05 | -3 58 | Re | 4 | 0.70 | 0.53-0.92 | .01 * | de | .10 | 52 | Fe | GS | RH |
| Caucasian | Ū | , - | <i>y</i> | | | J | Ū | | • | , - | <i>55</i>)- | | | | Ü | | | |
| Rc | 2 | 0.88 | 0.35-2.20 | .78 | de | 0.82 | 0 | Fe | | | | | | | | | | |
| Do | 2 | 0.85 | 0.50-1.47 | .57 | de | 0.73 | o | Fe | | | | | | | | | | |
| Co | 2 | 1.20 | 0.82-1.75 | .35 | in | 0.10 | 63 | Fe | | | | | | | | | | |

GD, genotype distribution; Rc, recessive; Do, dominant; Co, co dominant; n, number of studies; OR, odds ratio; CI, confidence interval; P^a , P-value for association; hp, higher in patients; hc, higher in controls; in, increased risk; de, decreased risk; P^b , P-value for heterogeneity (Het); I^2 , measure of variability; AM, analysis model; Re, random-effects; Fe, fixed-effects; PRO, pre-outlier; PSO, post-outlier; GS, gained significance (Sig); RNS, retained non- Sig; RH, reduced Het; EH, eliminated Het; values in bold indicate Sig associations; \star core outcome

Interleukin-18 figure captions and legends

Figure 1 Summary flowchart of literature search

Figure 2 Forest plot outcome in the allograft analysis of the codominant model

Diamond denotes the pooled odds ratio (OR) indicating reduced risk (0.89). Squares indicate the OR in each study. m, match. Horizontal lines on either side of each square represent the 95% confidence intervals (CI). The Z test for overall effect was non-significant ($P^1 = .48$). The χ^2 -test shows the presence of heterogeneity ($P^1 = .02$, $P^2 = .00$); $P^2 = .00$, $P^3 = .00$ 0, $P^3 = .00$ 1, $P^3 = .00$ 2, $P^3 = .00$ 3, $P^3 =$

Figure 3 Galbraith plot of the allograft analysis in the codominant model

m, match; Log OR, logarithm of standardized odds ratio; SE, standard error. The two studies above the +2 confidence limit are the outliers.

Figure 4 Forest plot outcome of outlier treatment in the allograft analysis of the codominant model

Diamond denotes the pooled odds ratio (OR) reduced risk (0.73). Squares indicate the OR in each study. m, match. Horizontal lines on either side of each square represent the 95% confidence intervals (CI). The Z test for overall effect shows significance ($P^{0} = .01$). The χ^{2} -test indicates reduced heterogeneity ($P^{0} = .16$, $I^{2} = 39\%$); I^{2} , a measure of variability expressed in %







